All In Biotech

Drug Trial Radar · NCT04675788

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

73

Actual

Start

Sep 2, 2021

Primary completion

Apr 16, 2025

Study completion Apr 16, 2025

Sponsor

Lead sponsor
Indiana UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Purdue University; National Heart, Lung, and Blood Institute (NHLBI); Harvard University; Cedars-Sinai Medical Center
First posted
Dec 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 99 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This research will determine if: 1) Oral progesterone attenuates drug-induced QT interval, J-Tpeak and Tpeak-Tend lengthening in postmenopausal women 50 years of age or older, and 2) Transdermal testosterone attenuates drug-induced QT interval, J-Tpeak and Tpeak-Tend lengthening in men 65 years of age or older. This investigation will consist of two concurrent prospective, randomized, double-blind, placebo-controlled crossover-design studies in a) Postmenopausal women, and b) Men 65 years of age or older. Study 1: Each postmenopausal woman will take progesterone or placebo capsules for 1 week. After a 14-day "washout" (no progesterone or placebo) each subject will then take the alternative therapy (progesterone or placebo) for 1 week. After 7 days of each treatment, subjects will present to the clinical research center to receive a small dose of the QT interval-lengthening drug ibutilide, and the effect on the QT, J-Tpeak and Tpeak-Tend intervals during the progesterone and placebo phases will be compared. Study 2: Each man 65 years of age or older will apply transdermal testosterone or transdermal placebo gel for 3 days. After a 7-day "washout" (no testosterone or placebo) each subject will then apply the alternative therapy (testosterone or placebo gel) for 1 week. After 3 days of each treatment, subjects will present to the clinical research center to receive a small dose of the QT interval-lengthening drug ibutilide, and the effect on the QT, J-Tpeak and Tpeak-Tend intervals during the testosterone and placebo phases will be compared.

Conditions

  • Long QT Syndrome
  • Abnormalities, Drug-Induced

Interventions

  • ProgesteroneDrug

    Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days

  • IbutilideDrug

    Ibutilide 0.003 mg/kg administered to all subjects to modestly lengthen the QT interval

  • TestosteroneDrug

    Subjects will apply transdermal testosterone gel once daily every morning for 3 days

  • PlaceboDrug

    Lactose capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pre-ibutilide QT-F and QT-Fram intervalsTime frame: Morning of day 8 (after 7 days of progesterone/placebo)
  2. Pre-ibutilide QT-F and QT-Fram intervalsTime frame: Morning of day 4 (after 3 days of testosterone/placebo)
  3. Maximum post-ibutilide QT-F and QT-Fram intervalsTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
  4. Percent change from baseline (pre-ibutilide) in maximum QT-F and QT-Fram intervalsTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
  5. Area under the QT-F and QT-Fram versus time curves during and for 1 hour following ibutilide infusionTime frame: From initiation of ibutilide infusion and for 1 hour after the end of ibutilide infusion
  6. Area under the QT-F and QT-Fram versus time curves during and for 8 hours following ibutilide infusionTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
  7. Pre-ibutilide heart rate-corrected J-Tpeak (J-Tpeakc) intervalsTime frame: Morning of day 8 (after 7 days of progesterone/placebo)
  8. Pre-ibutilide heart rate-corrected J-Tpeak (J-Tpeakc) intervalsTime frame: Morning of day 4 (after 3 days of testosterone/placebo)
  9. Maximum post-ibutilide J-Tpeakc intervalsTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
  10. Percent change from baseline (pre-ibutilide) in maximum J-Tpeakc intervalsTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
  11. Area under the J-Tpeakc versus time curve during and for 1 hour following ibutilide infusionTime frame: From initiation of ibutilide infusion and for 1 hour after the end of ibutilide infusion
  12. Area under the J-Tpeakc versus time curve during and for 8 hours following ibutilide infusionTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
  13. Pre-ibutilide Tpeak-Tend intervalsTime frame: Morning of day 8 (after 7 days of progesterone/placebo)
  14. Pre-ibutilide Tpeak-Tend intervalsTime frame: Morning of day 4 (after 3 days of testosterone/placebo)
  15. Maximum post-ibutilide Tpeak-Tend intervalsTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
  16. Percent change from baseline (pre-ibutilide) maximum Tpeak-Tend intervalsTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
  17. Area under the Tpeak-Tend versus time curves during and for 1 hour following ibutilide infusionTime frame: From initiation of ibutilide infusion and for 1 hour after the end of ibutilide infusion
  18. Area under the Tpeak-Tend versus time curves during and for 8 hours following ibutilide infusionTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Indiana Clinical Research Center

    Indianapolis, Indiana

  • Indiana University

    Indianapolis, Indiana

  • Purdue University

    Indianapolis, Indiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.